Logo

APYX

Apyx Medical Corporation

APYX

Apyx Medical Corporation • NASDAQ
$4.01 ▲ 0.00% (+0.00)
Market Cap $153.41 M
52w High $4.44
52w Low $0.76
Dividend Yield 0%
P/E -11.14
Volume 68.27K
Outstanding Shares 38.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.877M ▲ $9.129M ▼ $-1.984M ▲ -15.407% ▲ $0 ▲ $-332K ▲
Q2-2025 $11.373M ▲ $9.657M ▲ $-3.778M ▲ -33.219% ▲ $-0.093 ▲ $-2.164M ▲
Q1-2025 $9.43M ▼ $8.716M ▼ $-4.15M ▲ -44.008% ▼ $-0.12 $-2.609M ▲
Q4-2024 $14.222M ▲ $12.012M ▲ $-4.628M ▲ -32.541% ▲ $-0.12 ▲ $-2.775M ▲
Q3-2024 $11.487M $10.589M $-4.703M -40.942% $-0.14 $-3.089M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $25.135M ▼ $57.365M ▼ $51.285M ▲ $5.848M ▼
Q2-2025 $29.301M ▼ $58.188M ▼ $50.732M ▲ $7.253M ▼
Q1-2025 $31.011M ▼ $60.16M ▼ $49.516M ▼ $10.511M ▼
Q4-2024 $31.741M ▲ $64.842M ▲ $50.507M ▲ $14.21M ▲
Q3-2024 $28.013M $60.721M $49.524M $11.041M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.984M ▲ $-3.536M ▼ $-519K ▼ $45K ▲ $-4.166M ▼ $-4.055M ▼
Q2-2025 $-3.738M ▲ $-1.233M ▼ $-265K ▼ $25K $-1.71M ▼ $-1.498M ▼
Q1-2025 $-4.15M ▲ $-702K ▲ $-55K ▲ $25K ▼ $-730K ▼ $-757K ▲
Q4-2024 $-4.659M ▲ $-2.937M ▲ $-245K ▼ $6.76M ▲ $3.728M ▲ $-3.182M ▲
Q3-2024 $-4.768M $-4.44M $-153K $-5K $-4.665M $-4.593M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
OEM
OEM
 $0 ▲$0 ▲$0 ▲$0 ▲
Advanced Energy
Advanced Energy
 $20.00M ▲$10.00M ▼$10.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has been relatively small and has not grown much over the past several years. The company does generate solid gross margins on what it sells, but those margins are not nearly large enough to cover its operating costs. As a result, Apyx has posted operating and net losses year after year. Losses have been persistent rather than one‑off, which suggests the business is still in an investment and market‑building phase rather than a mature, profitable stage.

Balance Sheet

Balance Sheet The balance sheet is light, with a modest asset base and a noticeable decline in shareholders’ equity over time, reflecting ongoing losses. Cash remains an important part of total assets, but has been drifting down from prior levels. Debt, which was previously negligible, has now become a meaningful part of the capital structure. Overall, financial flexibility looks more limited than a few years ago, and the business appears increasingly reliant on outside funding to support operations.

Cash Flow

Cash Flow The company has consistently used cash in its day‑to‑day operations rather than generating it, which means it is effectively burning cash to fund growth and ongoing expenses. Free cash flow has been negative for several years, although capital spending has been modest, so the pressure mostly comes from operating losses rather than big investment projects. This pattern underscores the importance of either growing revenue meaningfully, improving cost efficiency, or securing additional financing to sustain the business.

Competitive Edge

Competitive Edge Apyx operates in a specialized corner of the medical device market, focused on energy‑based tools for cosmetic and surgical procedures. Its helium plasma platform, sold under the Renuvion and J‑Plasma brands, gives it a differentiated technology story versus more traditional laser or radiofrequency competitors. The company has built brand awareness among aesthetic surgeons and is developing a reputation around safety and tissue‑tightening outcomes. However, it is still a relatively small player in a field that includes much larger, well‑funded device makers, so maintaining and expanding share will likely depend on continued clinical evidence, strong training and support for surgeons, and successful commercial execution.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Apyx. The firm’s helium plasma technology is protected by a sizable patent portfolio across the U.S. and abroad, and management appears committed to backing the products with clinical research and peer‑reviewed data. The AYON body contouring system is a notable step forward, bringing several capabilities into one platform and aiming to simplify surgeons’ workflows. There are also efforts to expand indications, enter new geographies, and explore new clinical uses for cold plasma. All of this points to a company that is trying to turn a core technology platform into a broader ecosystem of products and procedures.

Summary

Apyx Medical combines a distinctive technology platform and active innovation engine with a financial profile that still reflects an early‑stage, loss‑making business. The company has carved out a niche in advanced energy devices for cosmetic and surgical use, supported by patents, brand recognition in its target markets, and growing clinical evidence. At the same time, revenue remains modest, profitability has not yet been reached, cash flow is consistently negative, and the balance sheet has grown weaker as equity shrinks and debt rises. The long‑term story depends on whether Apyx can translate its technical and clinical advantages into scale, sustainable profitability, and a stronger financial foundation while navigating competitive and regulatory pressures.

NEWS

November 18, 2025 · 7:30 AM UTC

Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock

Read more

November 17, 2025 · 4:05 PM UTC

Apyx Medical Corporation Announces Proposed Public Offering of Common Stock

Read more

October 23, 2025 · 8:00 AM UTC

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Read more